GlassScriptPhysician profile
Meredith H Covington
NPI 1821186917
$4,793.39
in general payments reported to CMS, 2019-2025
28 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $866 · 2022: $1,174 · 2023: $1,158 · 2024: $960 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $862.13 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $587.26 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $557.22 | 2021-2025 | Farxiga, Brilinta, Wainua |
| Pfizer INC. | $508.88 | 2021-2025 | |
| Boston Scientific Corporation | $483.61 | 2021-2025 | Watchman Access System |
| Merck Sharp & Dohme LLC | $368.01 | 2022-2024 | Verquvo, Keytruda |
| Abbott Laboratories | $229.17 | 2021-2024 | Gallant |
| E.R. Squibb & Sons, L.L.C. | $197.01 | 2022-2024 | Camzyos, Eliquis |
| Amgen INC. | $136.25 | 2022-2023 | Repatha |
| Alnylam Pharmaceuticals INC. | $132.60 | 2022-2025 | Amvuttra, Onpattro |
| Atricure, INC. | $88.45 | 2023 | |
| Janssen Pharmaceuticals, INC | $80.07 | 2022-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $72.83 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $65.33 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $51.87 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42.88 | 2024 | Injectafer |
| Medtronic, INC. | $42.52 | 2022 | |
| Philips North America LLC | $36.05 | 2025 | Lm Undivided |
| Heartflow, INC. | $34.88 | 2022 | |
| Bridgebio Pharma, INC. | $34.84 | 2025 | Attruby |
| Innovation Technologies INC | $32.04 | 2025 | Irrisept |
| United Therapeutics Corporation | $31.70 | 2025 | Tyvaso |
| Impulse Dynamics (USA) INC. | $29.52 | 2023 | Optimizer |
| Cvrx, INC. | $27.01 | 2023 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.63 | 2021-2022 | |
| Scpharmaceuticals INC. | $14.56 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $13.55 | 2023 | Uptravi, Opsumit |
| Chiesi USA, INC. | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Covington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.